COPD therapy Bevespi Aerosphere is now available in pharmacies across the US, according to an announcement by manufacturer AstraZeneca.
Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol was approved by the FDA in April 2016 for the long-term, maintenance treatment of airflow obstruction in patients with COPD. It is not indicated to treat asthma or for the relief of acute bronchospasm.
“At AstraZeneca, we are committed to following the science to improve the lives of people living with respiratory diseases. I’m thrilled that Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol is now available in pharmacies across the US,” said Tosh Butt, vice president, US Respiratory, AstraZeneca.
“An inhaled dual bronchodilator for the long-term maintenance treatment of COPD, Bevespi Aerosphere is the only LAMA/LABA in a pressurized metered dose inhaler – the most commonly used inhalation therapy delivery format in the US. It is also the first FDA-approved therapy using AstraZeneca’s novel Co-Suspension Delivery Technology. LAMA/LABA medicines are emerging as a preferred treatment option for many COPD patients – a treatment class that aims to provide maximum bronchodilation, enabling patients to breathe better and may help them be more active.”